1 Protocol Phase I study of intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma Principal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center
2 Malignant pleural mesothelioma (MPM) Approximately 3,000 cases /yr. in US Almost always a fatal disease Median survival 4-12 months 10% surgical candidates Resistant to chemotherapy and radiation therapy Only small incremental survival benefit with chemo + surgery +RT (MS 16 mos)
3 Malignant pleural mesothelioma (MPM) We have maximized potential benefit of traditional Rx paradigms Novel therapies needed
4 Viral Therapies for Mesothelioma Phase I trial of an HSV-tk-transduced ovarian cancer cell line (PA1-STK cells) infused ip followed by administration of ganciclovir LSU Hum Gene Therapy 9:2641, 1998 Phase 1 adenovirus delivery of herpes simplex thymidine kinase followed by ganciclovir as suicide gene therapy Univ Penn Clin Cancer Res 11:7444, 2005 A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions Univ Penn Mol. Ther. 18: 852, 2010 A phase I Trial of Oncolytic Measles Virotherapy with NIS reporter in Malignant Pleural Mesothelioma Mayo Clinic RAC protocol
5 Treatment of Mesothelioma by Vaccinia Virus MSTO211H MSTO211H JMN H2373 VAMT H2052 H2452 % Cell Survival D1 D2 D3 D4 D6 MOI 1.0 MOI 0.1 MOI 0.01 Days after infection Human Gene Therapy: 19:774, 2008
6 Infected Cells Support Viral Replication pfu/ml 4.00E E E E E E E E E+00 MSTO-211H Viral Growth Curve Day MOI 0.05 MOI 0.1 Cell Line Fold-increase MSTO-211H 3556 H H H VAMT 350 H-Meso 202 H-28 5
7 GLV-1h68 Treatment of Mesothelioma Intrapleural implantation of MSTO-211H cells Treatment ip with 1 X 10 7 PFU At 5 days (early) or 10 days (late) 600 Tumor Weight (mg) *p< **p< PBS controls Early Tx Late Tx Treatment Groups
8 GLV-1h68 Effectively Treats Pleural Mesothelioma GLV-1h68 Treated PBS Control
9 Survival after Treatment with GLV-1h68 Human Gene Therapy: 19:774, 2008
10 Virally-mediated GFP Expression Localizes Tumor Deposits on Chest Wall, Lung, and Diaphragm
11 Phase I Study: Intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma
12 Inclusion Criteria Pathologically proven malignant pleural effusions (MPM, met. NSCLC, other histologies) Free pleural space (partial or total) that permits the intrapleural drug instillation Age 18 years Acute toxicities of prior RT, chemorx, or surgery must have resolved to Grade 1 Chemotherapy, radiotherapy or immunotherapy must have stopped more than 14 days ECOG PS 0-1 No prior viral therapy
13 Study Schema Enrollment Administration of virus Biopsies of GFP positive and negative areas Presentation with malignant pleural effusion Drainage of pleural fluid with chest tube VATS for pleurodesis Evaluation for Toxicity
14 Dose level by cohort Cohort Dose ** Number of doses -1* Total volume of each injection Final volume of preparation will be 100 ml, to be administered as a bolus. * Necessary only if toxicity is encountered at the initial dose level. ** Intermediate dose levels may be evaluated if indicated.
15 Responses to Queries
16 Ornelles Question 3 Given that a strong selective pressure has been shown to silence transgene expression, could this not affect conclusions drawn from imaging patient tumors and non-tumor tissue at late times of therapy?...the viral progeny produced by multiple rounds of replication will have had a greater opportunity to silence reporter gene expression and detection by imaging methods alone could lead to a false negative conclusion. We will be assessing by VATS on days 2-7. We anticipate that the virus will have replicated no more than 3 cycles. We should be able to use the GFP marker gene for assessment of viral infection. Random pleural biopsies and GFP-directed biopsies will be performed to allow for assessment of viral presence. Viral plaque assays (VPA) will be performed to confirm presence of virus.
17 Strome Question 1 Why are 3 CT Scans necessary? RESPONSE: As an assessment of eligibility and for patient safety, the amount of free pleural space to permit infusion of treatment drug needs to be ascertained by CT scan during the screening has to determine if drainage is needed.
18 Strome Question 3 It is of interest to me from a company perspective and not this trial that immunosuppressive therapy is an exclusion criteria, yet in trial 1089, using the same viral construct giving combined chemo radiation therapy with this product is considered acceptable. Also in this study appropriately no chemotherapy or large field radiation therapy is being allowed. RESPONSE: As the route of intrapleural administration of GL-ONC1 has not been investigated in a phase I trial, clinical protocol was designed as a single agent treatment in order to determine the safety of this type of administration route. As such, chemotherapy, large field radiation therapy, or any other type of anti-cancer treatment is not allowed so as not to confound the results.
19 Strome: Consent Form Immune response further explained Risk of CT scan Chest tube further explained VATS (video assisted thoracoscopic surgery) further explained Treatment of generalized vaccinia infection further explained Thromboembolic event in Marsden trial added
20 Consent Form Chest tube and VATS standard therapy for this population Vaccinia treatment will be according to SOP in appendix Treatment of complications not covered by sponsor is standard for most phase 1 trials
21 Roizman Question 3 The clinical plan envisions testing GL-ONC1 by pleural drainage at days 2 and 3 after treatment. Implicit in this scheme is that the investigators do not think that the virus will persist and spread following initial infection. What is the rationale for testing patients after days 2 and 3 but not at later time to determine just how long does the infectious virus persist in the thoracic cavity? RESPONSE: The patients will also be tested on the day of pleurodesis, which is sometime between days 3-7. After that, we will no longer have easy access to the pleural cavity since the chest tube will be removed. Thus, we will stop assaying for virus not because we believe the virus will no longer persist, but because the pleural cavity will no longer be accessible.
22 Roizman Question 4 Please clarify whether VATS will be done for clinical indications or will VATS be required for this protocol RESPONSE: As stated in the Study Synopsis in section Assessment of Viral Appearance in Tumor, unless medically contraindicated, patients will under VATS This is done for: 1) comfort and functional status of patient 2) to facilitate future chemotherapy
23 Roizman Question 4 It can be expected that the side effects of the treatment (fever, flu like symptoms, etc) will occur in patients in whom the virus replicated to a high level? Will these patients be selected for thoracic surgery? RESPONSE: VATS is a standard medical practice to reduce the potential for a recurrence of pleural fluid in this patient population. Fever or flu-like symptoms would not be a determining factor in delaying thoracic surgery except in cases of sepsis.
What is Mesothelioma? Mesothelioma is a rare type of cancer that develops in the mesothelial cells found in one s body. These cells form membranous linings that surround and protect the body s organs and
Patient's Guide to Thoracic Cancer The Thoracic Oncology Program consists of an experienced team of nationally recognized cancer specialists experienced in the treatment of: Lung Cancer Tracheal Cancer
Mesothelioma Research Program Program Update 2012 We are pleased to provide you with an update of progress made over the past year in the Mesothelioma Research Program at The Princess Margaret / University
National Cancer Institute Taking Part in Cancer Treatment Research Studies U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Taking Part in Cancer Treatment Research Studies If
PLEURAL MESOTHELIOMA PLEURAL MESOTHELIOMA By: Domenico Galetta Institute of Oncology Giovanni Paolo II I.R.C.C.S. Oncology Hospital of Bari, Italy Silvia Novello University of Torino, Italy San Luigi Hospital
Eur Respir J 2010; 35: 479 495 DOI: 10.1183/09031936.00063109 CopyrightßERS Journals Ltd 2010 ERS/ESTS TASK FORCE Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons
E U R O P E A N J O U R NA L O F CA N C E R45 (2009) 228 247 available at www.sciencedirect.com journal homepage: www.ejconline.com New response evaluation criteria in solid tumours: Revised RECIST guideline
Malignant Pleural Mesothelioma NCCN Guidelines for Patients Presented with support from the national law firm of Baron & Budd Also available at NCCN.com About this booklet Its purpose Learning that you
European Medicines Agency London, 30 May 2008 Doc. Ref. EMEA/CHMP/GTWP/60436/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON FOLLOW-UP OF PATIENTS ADMINISTERED WITH GENE THERAPY
Clinical Trials: What You Need to Know Clinical trials are studies in which people volunteer to test new drugs or devices. Doctors use clinical trials to learn whether a new treatment works and is safe
The National Clinical Lung Cancer Audit (LUCADA) DATA MANUAL Title: Version: 3.1.5 Date: September 2013 LUCADA Lung Cancer Audit VERSION HISTORY Version Date Issued Brief Summary of Change Owner s Name
North America s Premiere Mesothelioma Program at Princess Margaret Cancer Centre Update Report July 2014 TABLE OF CONTENTS Introduction 3 Life-Changing Programs Now Underway 5 Mesothelioma Research Program
Evidence-based Series #7-14-2: Section 1 Surgical Management of Malignant Pleural Mesothelioma: A Clinical Practice Guideline D.E. Maziak, A. Gagliardi, A.E. Haynes, J.A. Mackay, W.K. Evans, and members
NCRI Lung CSG Mesothelioma workshop in association with Department of Health Workshop Report The Royal Society of Medicine, London 2nd May 2014 Sponsored by: Mesothelioma workshop Workshop Report Workshop
Guidance for Industry Expedited Programs for Serious Conditions Drugs and Biologics U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
Ann Ist Super Sanità 2009 Vol. 45, No. 2: 147-161 147 Health surveillance for subjects with past exposure to asbestos: from international experience and Italian regional practices to a proposed operational
A Patient s Guide to Mesothelioma What Is Mesothelioma? Causes and Risk Factors Finding a Specialist Treatment Options Legal Decisions Resources cure C a n c e r U p d at e s, R e s e a r c h & E d u c
Principal Principal Investigator s Investigator Organization Project Title Alan Pollack University of Miami Integrated Biomarker Profiling for Individualized Prostate Cancer Therapy General Project Abstract
BREATHE EASY HOW RADIOLOGY HELPS TO FIND AND FIGHT LUNG DISEASES TABLE OF CONTENTS 3 BREATHE EASY TABLE OF CONTENTS 4 INTRODUCTION: AN OVERVIEW OF CHEST IMAGING 9 CHAPTER 1: Lung imaging: the techniques
Handheld Radiofrequency Spectroscopy for Intraoperative Margin Assessment During Breast-Conserving Surgery Assessment Program Volume 28, No. 4 August 2013 Executive Summary Background Breast-conserving
DEPARTMENT OF HEALTH & HUMAN SERVICXS Public Health Service l.l l_-l- Ix, ^. ^ ^ _-_^_ ~,,-^ Food and Drug Administration Alfred E. Chang, M.D. Department of Surgery University of Michigan Comprehensive
Access to Electronic Thesis Author: Thesis title: Qualification: Helen Clayson The Experience of Mesothelioma in Northern England MD This electronic thesis is protected by the Copyright, Designs and Patents
& MALIGNANT PLEURAL MESOTHELIOMA TREATED IN CLINIC FOR PULMONARY DISEASES AND TUBERCULOSIS PODHRASTOVI IN TEN-YEAR PERIOD ( FROM 1998 TO 2007 ) Vesna Čukić*, Aida Ustamujić, Vladimir Lovre, Hasan Žutić,